Quotient Clinical completes innovative first-in-human program
[wp_ad_camp_4]Quotient Clinical, the Translational Pharmaceutics® Company, has announced the publication of results from an Enabled-First-in-Human (Enabled-FIH) program conducted for the Janssen WAVE Early Development unit. The integrated pharmaceutical development and first-in-human clinical program was designed to develop an optimal oral formulation, in parallel with